Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

نتائج البحث

Display Settings
النتائج لكل صفحة: 10
Sort By: Relevance
Filter
  • 1-10 ل  8,387 نتائج ل ""+drug therapy""

فلترة النتائج

Subject : antineoplastic combined chemotherapy protocols
إعادة تعيين خيارات الفبترة
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre-clinical study.

  • Authors : Low K; Department of Natural Sciences, Middlesex University, London, UK.; Foulkes P

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/adverse effects ; Bone Neoplasms*/Bone Neoplasms*/Bone Neoplasms*/drug therapy

  • Source: Cancer medicine [Cancer Med] 2024 Sep; Vol. 13 (18), pp. e70248.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma.

  • Authors : Lin Z; Department of Interventonal Medicine, Zhongshan People's Hospital, Guangdong, 528400, China.; Zou X

Subjects: Cholangiocarcinoma*/Cholangiocarcinoma*/Cholangiocarcinoma*/drug therapy ; Cholangiocarcinoma*/Cholangiocarcinoma*/Cholangiocarcinoma*/pathology ; Quinolines*/Quinolines*/Quinolines*/therapeutic use

  • Source: Scientific reports [Sci Rep] 2024 Oct 14; Vol. 14 (1), pp. 23961. Date of Electronic Publication: 2024 Oct 14.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.

Subjects: Melanoma*/Melanoma*/Melanoma*/drug therapy ; Melanoma*/Melanoma*/Melanoma*/pathology ; Melanoma*/Melanoma*/Melanoma*/mortality

  • Source: BMC cancer [BMC Cancer] 2024 Oct 01; Vol. 24 (1), pp. 1220. Date of Electronic Publication: 2024 Oct 01.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer.

  • Authors : Xie CK; Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.; Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fuzhou, 350001, China.

Subjects: Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/pharmacology ; Gemcitabine*

  • Source: Molecular cancer [Mol Cancer] 2024 Sep 30; Vol. 23 (1), pp. 215. Date of Electronic Publication: 2024 Sep 30.Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer.

  • Authors : Urabe M; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.; Ikezawa K

Subjects: Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/drug therapy ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/pathology ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/metabolism

  • Source: Scientific reports [Sci Rep] 2024 Sep 20; Vol. 14 (1), pp. 21953. Date of Electronic Publication: 2024 Sep 20.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol.

  • Authors : Budillon A; Scientific Directorate, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy. .; Leone A

Subjects: Albumins*/Albumins*/Albumins*/administration & dosage ; Albumins*/Albumins*/Albumins*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use

  • Source: BMC cancer [BMC Cancer] 2024 Sep 19; Vol. 24 (1), pp. 1167. Date of Electronic Publication: 2024 Sep 19.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.

  • Authors : Alcantara M; CellAction, Center for Cancer Immunotherapy, Institut Curie, Suresnes, France.; Clinical Hematology Unit, Institut Curie, Saint-Cloud, 92210, France.

Subjects: Lenalidomide*/Lenalidomide*/Lenalidomide*/administration & dosage ; Lenalidomide*/Lenalidomide*/Lenalidomide*/therapeutic use ; Lenalidomide*/Lenalidomide*/Lenalidomide*/adverse effects

  • Source: Journal of hematology & oncology [J Hematol Oncol] 2024 Sep 19; Vol. 17 (1), pp. 86. Date of Electronic Publication: 2024 Sep 19.Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial.

  • Authors : Tang Q; Department of Musculoskeletal Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Subjects: Osteosarcoma*/Osteosarcoma*/Osteosarcoma*/drug therapy ; Osteosarcoma*/Osteosarcoma*/Osteosarcoma*/mortality ; Osteosarcoma*/Osteosarcoma*/Osteosarcoma*/therapy

  • Source: Cancer medicine [Cancer Med] 2024 Sep; Vol. 13 (18), pp. e70206.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.

Subjects: Paclitaxel*/Paclitaxel*/Paclitaxel*/administration & dosage ; Paclitaxel*/Paclitaxel*/Paclitaxel*/therapeutic use ; Paclitaxel*/Paclitaxel*/Paclitaxel*/adverse effects

  • Source: BMC cancer [BMC Cancer] 2024 Jul 22; Vol. 24 (1), pp. 876. Date of Electronic Publication: 2024 Jul 22.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.

  • Authors : Olawaiye AB; University of Pittsburgh School of Medicine and Magee-Womens Hospital, Gynecologic Oncology Group, Pittsburgh, PA, USA. .; Kim JW

Subjects: Albumins*/Albumins*/Albumins*/administration & dosage ; Albumins*/Albumins*/Albumins*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use

  • Source: Journal of gynecologic oncology [J Gynecol Oncol] 2024 Jul; Vol. 35 (4), pp. e111.Publisher: Asian Society of Gynecologic Oncology Country of Publication: Korea (South) NLM ID: 101483150 Publication Model: Print Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
  • 1-10 ل  8,387 نتائج ل ""+drug therapy""